"The U.S. Food and Drug Administration today approved Opsumit (macitentan), a new drug to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive and debilitating disease that can lead to death or the need for lung transpla"...
- Clinician Information:
Tudorza Pressair Side Effects Center
Medical Editor: Charles Patrick Davis, MD, PhD
Tudorza Pressair (aclidinium bromide) inhalation powder is an anticholinergic indicated for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. The most common side effects of Tudorza Pressair are headache, common cold symptoms, and cough.
Tudorza Pressair is available for oral inhalation only. The recommended dosage of Tudorza Pressair is one inhalation (400 mcg of aclidinium bromide) twice daily. Some serious side effects of Tudorza Pressair can include sudden shortness of breath immediately after taking this medicine and new or worsened pressure in the eyes (acute narrow-angle glaucoma).There are no adequate and well controlled studies in pregnant women. Tudorza Pressair should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Excretion of aclidinium bromide, the active ingredient in Tudorza Pressair into human breast milk is probable. There are no human studies that have investigated the effects of Tudorza Pressair on breastfed infants. Caution should be exercised when Tudorza Pressair is administered to nursing women. The safety and effectiveness in the pediatric population has not been established.
Our Tudorza Pressair Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Tudorza Pressair FDA Prescribing Information: Side Effects
The following adverse reactions are described in greater detail in other sections:
- Paradoxical bronchospasm [see WARNINGS AND PRECAUTIONS]
- Worsening of narrow-angle glaucoma [see WARNINGS AND PRECAUTIONS]
- Worsening of urinary retention [see WARNINGS AND PRECAUTIONS]
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
3-Month and 6-Month Trials
TUDORZA PRESSAIR was studied in two 3-month (Trials B and C) and one 6-month (Trial D) placebo-controlled trials in patients with COPD. In these trials, 636 patients were treated with TUDORZA PRESSAIR at the recommended dose of 400 mcg twice daily.
The population had a mean age of 64 years (ranging from 40 to 89 years), with 58% males, 94% Caucasian, and had COPD with a mean pre-bronchodilator forced expiratory volume in one second (FEV1) percent predicted of 48%. Patients with unstable cardiac disease, narrow-angle glaucoma, or symptomatic prostatic hypertrophy or bladder outlet obstruction were excluded from these trials.
Table 1 shows all adverse reactions that occurred with a frequency of greater than or equal to 1% in the TUDORZA PRESSAIR group in the two 3-month and one 6-month placebo-controlled trials where the rates in the TUDORZA PRESSAIR group exceeded placebo.
Table 1: Adverse Reactions (°/o Patients) in Placebo-Controlled
| Adverse Reactions
|n (%)||n (%)|
|Headache||42 (6.6)||32 (5.0)|
|Cough||19 (3.0)||14 (2.2)|
In addition, among the adverse reactions observed in the clinical trials with an incidence of less than 1% were diabetes mellitus, dry mouth, 1st degree AV block, osteoarthritis, cardiac failure, and cardio-respiratory arrest.
Long-term Safety Trials
TUDORZA PRESSAIR was studied in three long term safety trials, two double blind and one open label, ranging from 40 to 52 weeks in patients with moderate to severe COPD. Two of these trials were extensions of the 3-month trials, and one was a dedicated long term safety trial. In these trials, 891 patients were treated with TUDORZA PRESSAIR at the recommended dose of 400 mcg twice daily. The demographic and baseline characteristics of the long term safety trials were similar to those of the placebo-controlled trials. The adverse events reported in the long term safety trials were similar to those occurring in the placebo-controlled trials of 3 to 6 months. No new safety findings were reported compared to the placebo controlled trials.
Read the entire FDA prescribing information for Tudorza Pressair (Aclidinium Bromide) »
Additional Tudorza Pressair Information
- Tudorza Pressair Drug Interactions Center: aclidinium bromide inhl
- Tudorza Pressair Side Effects Center
- Tudorza Pressair FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.